Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IRWD
  • CUSIP: 46333X10
  • Web:
  • Market Cap: $2.77 billion
  • Outstanding Shares: 148,616,000
Average Prices:
  • 50 Day Moving Avg: $16.82
  • 200 Day Moving Avg: $16.31
  • 52 Week Range: $12.03 - $19.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -62.07
  • P/E Growth: -0.39
Sales & Book Value:
  • Annual Revenue: $260.08 million
  • Price / Sales: 10.64
  • Book Value: $0.20 per share
  • Price / Book: 93.10
  • EBIDTA: ($64,810,000.00)
  • Net Margins: -34.29%
  • Return on Equity: -94.17%
  • Return on Assets: -11.60%
  • Debt-to-Equity Ratio: 6.10%
  • Current Ratio: 4.02%
  • Quick Ratio: 4.02%
  • Average Volume: 1.49 million shs.
  • Beta: 1.34
  • Short Ratio: 8.97

Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.14. The business had revenue of $52.16 million for the quarter, compared to the consensus estimate of $69.39 million. Ironwood Pharmaceuticals had a negative net margin of 34.29% and a negative return on equity of 94.17%. The business's revenue was down 21.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.08) EPS. View Ironwood Pharmaceuticals' Earnings History.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

9 brokers have issued twelve-month price objectives for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $22.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $18.44 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.

Are investors shorting Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 14,337,725 shares, a drop of 8.4% from the April 28th total of 15,650,463 shares. Based on an average trading volume of 1,897,249 shares, the days-to-cover ratio is presently 7.6 days. Approximately 10.8% of the shares of the stock are sold short.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (13.11%), Vanguard Group Inc. (7.11%), Janus Capital Management LLC (5.33%), Brown Capital Management LLC (3.44%), State Street Corp (2.68%) and EcoR1 Capital LLC (1.96%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Metropolitan Life Insurance Co. NY, Granahan Investment Management Inc. MA, Rubric Capital Management LP, FMR LLC, Morgan Stanley, Bank of Nova Scotia and Blue Jay Capital Management LLC. Company insiders that have sold Ironwood Pharmaceuticals stock in the last year include Gina Consylman, Halley E Gilbert, Lawrence S Olanoff, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Point72 Asset Management L.P., UBS Asset Management Americas Inc., Pictet Asset Management Ltd., Vanguard Group Inc., Gotham Asset Management LLC, State Street Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ironwood Pharmaceuticals stock cost?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $18.62.

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (?)
Ratings Breakdown: 4 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $18.44 (0.94% downside)

Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Cowen and CompanyReiterated RatingOutperform$20.00HighView Rating Details
5/9/2017WedbushReiterated RatingNeutral$13.00HighView Rating Details
5/3/2017Wells Fargo & CoInitiated CoverageOutperform -> Outperform$22.00HighView Rating Details
4/7/2017MizuhoBoost Price TargetBuy -> Buy$21.00 -> $22.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017Barclays PLCReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
2/2/2017JPMorgan Chase & Co.Set Price TargetBuy$21.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
4/26/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/23/2016Wood & CompanyInitiated CoveragePositiveN/AView Rating Details
3/21/2016Goldman Sachs Group IncInitiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.20)($0.22)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.21)($0.12)($0.17)
Q4 20172($0.19)($0.10)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.17%
Institutional Ownership Percentage: 96.01%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.00View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateHeadline logoIronwood Pharmaceuticals, Inc. (IRWD) Short Interest Down 8.4% in May - May 27 at 7:18 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Insider Sells $546,000.00 in Stock - May 16 at 7:32 PM logo-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter - May 12 at 10:20 PM logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : May 11, 2017 - May 11 at 11:38 PM logoWedbush Analysts Reduce Earnings Estimates for Ironwood Pharmaceuticals, Inc. (IRWD) - May 11 at 8:32 AM logoIronwood Pharma (IRWD) Presents Data Further Elucidating Linaclotide's Effect on Pain at DDW - May 10 at 6:18 PM logoIronwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference - May 10 at 6:18 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Earn FY2019 Earnings of $0.76 Per Share - May 10 at 2:54 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : May 10, 2017 - May 10 at 1:16 PM logoIronwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017 - May 9 at 5:45 PM logoIronwood Pharmaceuticals Provides First Quarter 2017 Investor Update - May 9 at 12:19 PM logoEdited Transcript of IRWD earnings conference call or presentation 8-May-17 12:30pm GMT - May 9 at 12:19 PM logoIronwood (IRWD) Q1 Loss Wider than Expected, Sales Miss - May 9 at 12:18 PM logoIronwood Pharmaceuticals' (IRWD) "Outperform" Rating Reaffirmed at Cowen and Company - May 9 at 9:48 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Issues Earnings Results, Misses Expectations By $0.15 EPS - May 8 at 11:32 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS - May 8 at 9:40 PM logoIronwood reports 1Q loss - May 8 at 8:41 AM logoInvestor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - May 8 at 7:52 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Average Recommendation of "Hold" from Brokerages - May 5 at 10:43 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives New Coverage from Analysts at Wells Fargo & Co - May 3 at 10:26 AM logoIronwood Pharmaceuticals (IRWD) Receives Daily News Impact Score of 0.40 - May 3 at 12:50 AM logoIronwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week ® 2017 - May 1 at 1:13 PM logoIronwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017 - May 1 at 1:13 PM logoResearch Analysts Offer Predictions for Ironwood Pharmaceuticals, Inc.'s Q2 2017 Earnings (IRWD) - May 1 at 8:11 AM logoIronwood Pharmaceuticals, Inc. Expected to Post Q1 2018 Earnings of ($0.15) Per Share (IRWD) - April 28 at 10:00 PM logoSomewhat Positive Media Coverage Unlikely to Affect Ironwood Pharmaceuticals (IRWD) Share Price - April 28 at 5:56 PM logoQ1 2017 EPS Estimates for Ironwood Pharmaceuticals, Inc. Cut by Leerink Swann (IRWD) - April 27 at 7:38 AM logoBrokers Issue Forecasts for Ironwood Pharmaceuticals, Inc.'s FY2018 Earnings (IRWD) - April 26 at 4:48 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $73.15 Million - April 26 at 2:20 PM logoIronwood Pharmaceuticals (IRWD) Receiving Somewhat Positive Media Coverage, Analysis Shows - April 25 at 9:34 PM logoIronwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call - April 24 at 5:38 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.19 Per Share - April 24 at 10:12 AM logoSomewhat Positive News Coverage Very Likely to Affect Ironwood Pharmaceuticals (IRWD) Share Price - April 21 at 9:50 PM logoIronwood Pharmaceuticals Becomes Oversold (IRWD) - April 19 at 11:20 AM logoAre Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock? - April 18 at 10:59 AM logoSomewhat Critical Press Coverage Somewhat Unlikely to Affect Ironwood Pharmaceuticals (IRWD) Share Price - April 17 at 9:03 PM logoIronwood Pharmaceuticals (IRWD) Earning Somewhat Positive Press Coverage, Study Finds - April 15 at 12:45 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Given a $20.00 Price Target at Cowen and Company - April 13 at 8:08 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Sees Significant Decrease in Short Interest - April 13 at 6:19 PM logoAllergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5) - April 13 at 9:30 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Rating of "Hold" from Brokerages - April 10 at 10:46 PM logoIronwood Pharmaceuticals (IRWD) PT Raised to $22 at Mizuho Securities; 'Bullish on IW-3718 Refractory GERD ... - - April 8 at 9:01 AM logoIronwood Pharmaceuticals, Inc. (IRWD) PT Raised to $22.00 at Mizuho - April 7 at 5:31 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : April 5, 2017 - April 7 at 10:29 AM logoIronwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer - April 7 at 10:29 AM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : April 6, 2017 - April 7 at 10:29 AM logoIRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin - March 30 at 6:22 PM logoFirst Week of November 17th Options Trading For Ironwood Pharmaceuticals (IRWD) - March 21 at 5:57 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Rating Reiterated by Mizuho - March 17 at 11:19 AM logoIronwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference 2017 - March 16 at 6:48 PM



Ironwood Pharmaceuticals (IRWD) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff